Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Nature communications · 2025
    RJRebecca J Craig-SchapiroJMJesus Maria Gomez SalineroAKAleksandra KopaczRSRyan Schreiner+1 more →DRDavid Redmond
    PMID: 39915484PMCID: PMC11802906DOIFirst author22 citations
  2. 2
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    RJRebecca J Craig-SchapiroTSThalia SalinasMLMichelle LubetzkyJRJohn Richard Lee+2 more →DMDarshana M Dadhania
    PMID: 33043597PMCID: PMC7675359DOIFirst author78 citations
  3. 3
    The Journal of surgical research · 2020
    RJRebecca J Craig-Schapiro
    PMID: 32563759PMCID: PMC7541744DOIFirst author2 citations

Publications

24 publications

Funding

5 grantsView NIH portfolio on RePORTER ↗

Active

4 grants
  • PI
    Molecular determinants of islet-specific endothelium for regulation of beta-cell homeostasis
    National Institute of Diabetes and Digestive and Kidney Diseases · 2026–2031
    K08DK147686-01
  • Co-I
    Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts
    Juvenile Diabetes Research Foundation · 2024–2026 · via Columbia University
    2-SRA-2024-1525-S-B
  • Co-I
    Co-transplantation of adaptive human endothelium and islets within encapsulated angiogenic hydrogels for durable engraftment
    Juvenile Diabetes Research Foundation · 2023–2026
    3-SRA-2023-1446-S-B
  • Co-I
    Subcutaneous transplantation of Islet-specific endothelial cell vascularized islets to treat diabetes
    Daedalus Fund for Innovation (Weill Cornell) · 2024–2026BioPharma Alliance
    BP 242176-01
Completed grants (1)
  • Co-I
    Subcutaneous Transplantation of Pre-Vascularized Human Islets and SC-β cells to Treat Type I Diabetes
    Juvenile Diabetes Research Foundation · 2022–2024
    JDRF 220093-01

Clinical research

1 study
Completed & closed trials (1)
  • PI
    A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation
    PHASE2 · Alexion Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2026)
    Antibody-Mediated Rejection; Kidney Transplantation; Biopsy-proven Histologic Scores; AMR
    NCT06744647

News mentions

1 mentionView all WCM news ↗